WallStSmart

Insmed Inc (INSM)vsUniqure NV (QURE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 3667% more annual revenue ($606.42M vs $16.10M). QURE leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

QURE

Avoid

22

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

QURE0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

QURE4 concerns · Avg: 2.5/10
Market CapQuality
$949.20M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-2.1%2/10

ROE of -2.1% — below average capital efficiency

EPS GrowthGrowth
-18.2%2/10

Earnings declined 18.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : QURE

QURE has a balanced fundamental profile.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : QURE

The primary concerns for QURE are Market Cap, Profit Margin, Return on Equity.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while QURE is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

QURE is growing revenue faster at 6.6% — sustainability is the question.

QURE generates stronger free cash flow (-78M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Uniqure NV

HEALTHCARE · BIOTECHNOLOGY · USA

uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?